ATYR aTyr Pharma, Inc. - Common Stock
$0.53
मूल्य · अग 18, 2026
मौलिकता इस प्रकार है अग 7, 2026
52W रेंज
$0–$6
2% of range
विश्लेषक रेटिंग
BUY
15 analysts
मूल्य लक्ष्य
$3
+439% upside
P/E (TTM)
-0.7
ROE
-107.8%
शुद्ध लाभ मार्जिन
-39009.5%
aTyr Pharma, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
और पढ़ें
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
History
In 2005, aTyr was founded by Paul Schimmel, and Xiang-Lei Yang, two aminoacyl tRNA synthetase scientists at The Scripps Research Institute. In 2009, Bruce Beutler, recipient of the 2011 Nobel Prize in Physiology or Medicine, joined aTyr as a member of the scientific advisory board.
In April 2007, Polaris Partners and Alta Partners co-led a $10.5 million Series B financing. In October 2010, Series C financing totaled $23 million and was led by Domain Associates. This round was followed by a $49 million Series D in August 2013.
aTyr was a winner of the 2011 Red Herring 100 North America Award for discovering and developing innovative medicines based on Physiocrine biology.
In April 2015, aTyr raised $76 million in a Series E, led by Sofinnova Ventures, and filed for an IPO. The company began trading as LIFE on the Nasdaq stock exchange.
ATyr's primary focus is on ATYR1923, a clinical stage product candidate which binds to the NRP2 receptor and is designed to down regulate immune engagement in interstitial lung diseases (ILDs). ATYR1923 is currently being investigated in a clinical trial in patients with pulmonary sarcoidosis. In January 2020, ATyr entered into a license with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. Under the license agreement, Kyorin received an exclusive right to develop and commercialize ATYR1923 in Japan for all forms of ILDs including, sarcoidosis, chronic hypersensitivity pneumonitis (CHP) and connective tissue disease ILD (CTD-ILD). aTyr recently initiated a clinical trial for ATYR1923 in patients with severe respiratory complications related to COVID-19.
Therapeutic concept
Homeostasis, or the coordinated regulation of tissues within the body, is fundamental to the maintenance of the overall health of an organism. Lack of homeostasis can lead to disease and death. The process of homeostasis was first described in 1865 by the French physiologist Claude Bernard and Walter Cannon later coined the term. In the 150 years since this discovery, many proteins associated with homeostatic pathways have been discovered, ranging from insulin to erythropoietin.
aTyr was founded after Dr. Schimmel discovered several nontranslational functions of aminoacyl tRNA synthetases, which are primarily responsible for the production of a vital component of protein synthesis, aminoacyl-tRNAs. [23] These nontranslational functions have since been shown to play an important role in maintaining homeostasis. [23] One of these nontranslational functions is modulation and regulation of the immune response. [23] This modulatory activity is a result of Physiocrines, a novel class of proteins that are present as biologically active signaling regions of the tRNA synthetases. aTyr's research is based on the premise that Physiocrines are involved in orchestrating homeostatic activities to help the body restore diseased or damaged tissue to a healthier state.
By researching and understanding the role of Physiocrines in immune modulation, aTyr has developed two IND candidates.
== References ==
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
ATYR स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
मूल्य
$0.53
मार्केट कैप
$52M
P/E (TTM)
-0.7
EPS (TTM)
$-0.80
राजस्व (TTM)
$190.0K
लाभांश प्रतिफल
—
ROE
-107.8%
D/E ऋण/इक्विटी
—
52W रेंज
$0 – $7
ATYR स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
Configure
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
राजस्व और शुद्ध आय
$190.0K
2019-12-31
→
2025-12-31
EPS
$-0.80
2020-12-31
→
2025-12-31
फ्री कैश फ्लो
$-62M
2016-12-31
→
2025-12-31
मार्जिन
-39009.5%
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
मेट्रिक
5Y रुझान
ATYR
सहकर्मी माध्यिका
P/E (TTM)
-0.7
—
P/S (TTM)
273.4
165.8
P/B
0.8
1.6
Price / FCF (मूल्य / FCF)
-0.8
—
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
मेट्रिक
5Y रुझान
ATYR
सहकर्मी माध्यिका
Operating Margin (परिचालन मार्जिन)
-40856.3%
—
Net Profit Margin (शुद्ध लाभ मार्जिन)
-39009.5%
-2229.6%
ROA
-78.1%
-64.3%
ROE
-107.8%
-102.1%
ROIC
-115.0%
—
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
मेट्रिक
5Y रुझान
ATYR
सहकर्मी माध्यिका
Current Ratio (वर्तमान अनुपात)
5.3
4.8
Quick Ratio (त्वरित अनुपात)
0.7
—
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
मेट्रिक
5Y रुझान
ATYR
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
-19.1%
—
Revenue CAGR 3Y (राजस्व CAGR 3Y)
-73.7%
—
Revenue CAGR 5Y (राजस्व CAGR 5Y)
-55.1%
—
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
मेट्रिक
5Y रुझान
ATYR
सहकर्मी माध्यिका
ATYR विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
खरीदें
15 विश्लेषक
- मजबूत खरीद 3 20.0%
- खरीदें 6 40.0%
- होल्ड 6 40.0%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
7 विश्लेषक · 2026-08-13
मध्यिका
$3.00
← सभी लक्ष्यों से नीचे
$0.53
निम्न
$1.00
उच्च
$7.00
मध्यिका लक्ष्य
$3.00
+466.1%
माध्य लक्ष्य
$2.86
+439.2%
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
औसत आश्चर्य
0.01%
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $-0.11 | $-0.12 | 0.01% |
| 31 मार्च 2026 | $-0.11 | $-0.14 | 0.03% |
| 31 दिसमबर 2025 | $-0.14 | $-0.19 | 0.05% |
| 30 सितमबर 2025 | $-0.26 | $-0.19 | -0.07% |
| 30 जून 2025 | $-0.22 | $-0.19 | -0.03% |
| 31 मार्च 2025 | $-0.17 | $-0.19 | 0.02% |
| 31 दिसमबर 2024 | $-0.18 | $-0.23 | 0.05% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| ATYR | $77M | -1.0 | -19.1% | -39009.5% | -107.8% | — |
| TCRX | — | -1.0 | 266.7% | -1256.8% | -86.6% | — |
| APLM | — | — | — | — | — | — |
| TIL | $75M | -1.0 | — | — | -58.1% | — |
| MGX | $61M | -0.7 | -51.8% | -348.5% | -49.6% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10M | $0 | $10M | $422.0K | |
| R&D Expense | $60M | $54M | $42M | $43M | $23M | $17M | $14M | |
| SG&A Expense | $18M | $14M | $13M | $14M | $11M | $9M | $9M | |
| Operating Expenses | $78M | $68M | $55M | $57M | $34M | $26M | $23M | |
| Operating Income | $-78M | $-68M | $-55M | $-46M | $-34M | $-16M | $-23M | |
| Other Non-op | $4M | $4M | $5M | $1M | $238.0K | $-319.0K | $-785.0K | |
| Pretax Income | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-24M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-16M | |
| EPS (Basic) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · | |
| EPS (Diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · | |
| Shares (Basic) | 92,985,359 | 74,261,265 | 53,606,488 | 28,419,569 | 19,080,878 | 9,160,269 | · | |
| Shares (Diluted) | 92,985,359 | 74,261,265 | 53,606,488 | 28,419,569 | 19,080,878 | 9,160,269 | · | |
| EBITDA | $-77M | $-67M | $-54M | $-46M | $-34M | $-15M | $-22M |
बैलेंस शीट 20
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $11M | $23M | $10M | $2M | $17M | $9M | |
| Prepaid Expense | $677.0K | $8M | $2M | $3M | $5M | $2M | $681.0K | |
| Current Assets | $80M | $82M | $103M | $81M | $114M | $36M | $32M | |
| PP&E (Net) | $4M | $5M | $6M | $3M | $543.0K | $899.0K | $1M | |
| PP&E (Gross) | $9M | $9M | $10M | $9M | $7M | $8M | $7M | |
| Accum. Depreciation | $5M | $5M | $5M | $6M | $6M | $7M | $6M | |
| Other Non-current Assets | $148.0K | $66.0K | $131.0K | $193.0K | $158.0K | $213.0K | $172.0K | |
| Total Assets | $93M | $97M | $121M | $96M | $116M | $39M | $36M | |
| Accounts Payable | $4M | $4M | $4M | $3M | $1M | $1M | $847.0K | |
| Accrued Liabilities | $10M | $9M | $12M | $10M | $4M | $4M | $2M | |
| Current Liabilities | $15M | $15M | $16M | $14M | $6M | $6M | $13M | |
| Capital Leases | $10M | $11M | $12M | $10M | $398.0K | $1M | $2M | |
| Total Debt | · | · | · | · | · | · | $9M | |
| Common Stock | $98.0K | $84.0K | $63.0K | $29.0K | $28.0K | $11.0K | $4.0K | |
| Paid-in Capital | $674M | $602M | $559M | $490M | $482M | $370M | $344M | |
| Retained Earnings | $-606M | $-532M | $-468M | $-418M | $-372M | $-339M | $-322M | |
| AOCI | $-8.0K | $-40.0K | $-74.0K | $-433.0K | $-263.0K | $-43.0K | $-40.0K | |
| Stockholders' Equity | $67M | $70M | $91M | $71M | $109M | $32M | $21M | |
| Liabilities + Equity | $93M | $97M | $121M | $96M | $116M | $39M | $36M | |
| Shares Outstanding | 98,031,014 | 84,038,922 | 63,286,404 | 29,498,488 | 27,793,035 | 11,018,954 | 3,891,787 |
नकदी प्रवाह 8
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $664.0K | $708.0K | $592.0K | $232.0K | $475.0K | $569.0K | $635.0K | |
| Other Non-cash | $11M | $-6M | $17M | $3M | $218.0K | $354.0K | $3M | |
| Operating Cash Flow | $-62M | $-69M | $-33M | $-42M | $-33M | $-15M | $-20M | |
| CapEx | $77.0K | $65.0K | $4M | $2M | $192.0K | $202.0K | $79.0K | |
| Investing Cash Flow | $-5M | $17M | $-20M | $47M | $-92M | $7M | $5M | |
| Financing Cash Flow | $66M | $40M | $66M | $5M | $110M | $16M | $1M | |
| Net Change in Cash | $-1M | $-12M | $13M | $11M | $-15M | $8M | $-14M | |
| Free Cash Flow | $-62M | $-69M | $-37M | $-44M | $-33M | $-16M | $-20M |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -40856.3% | -28899.6% | -15557.8% | -446.8% | · | -152.2% | -5445.0% | |
| Net Margin | -39009.5% | -27243.8% | -14274.5% | -436.5% | · | -155.2% | -5593.1% | |
| Pretax Margin | -39012.1% | -27243.4% | -14276.2% | -436.6% | · | -155.2% | -5631.0% | |
| EBITDA Margin | -40506.8% | -28598.3% | -15390.1% | -444.6% | · | -146.7% | -5294.6% | |
| ROA | -78.1% | -58.9% | -46.6% | -42.9% | -43.8% | -43.3% | -53.1% | |
| ROE | -107.8% | -79.7% | -62.2% | -50.2% | -47.9% | -61.4% | -98.5% | |
| ROIC | -115.0% | -97.0% | -60.6% | -64.9% | -31.1% | -50.3% | · |
तरलता और शोधन क्षमता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.3 | 5.5 | 6.3 | 5.8 | 18.9 | 6.1 | 2.5 | |
| Quick Ratio | 0.7 | 0.7 | 1.4 | 0.7 | 0.4 | 2.9 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | 0.4 |
दक्षता 1
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.1 | · | 0.3 | 0.0 |
विकास दरें 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -19.1% | -33.4% | -96.6% | · | · | · | · | |
| Revenue CAGR 3Y | -73.7% | · | -67.7% | · | · | · | · | |
| Revenue CAGR 5Y | -55.1% | · | · | · | · | · | · |
मूल्यांकन (TTM) 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $190.0K | $235.0K | $353.0K | $10M | $0 | $10M | $422.0K | |
| Net Income TTM | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-16M | |
| Market Cap | $77M | $304M | $89M | $65M | $208M | $43M | $16M | |
| Enterprise Value | · | · | · | · | · | · | $16M | |
| P/E | -1.0 | -4.2 | -1.5 | -1.4 | -4.2 | -2.2 | · | |
| P/S | 404.0 | 1294.6 | 252.8 | 6.2 | · | 4.1 | 38.5 | |
| P/B | 1.1 | 4.3 | 1.0 | 0.9 | 1.9 | 1.4 | 0.8 | |
| P / Tangible Book | 1.1 | 4.3 | 1.0 | 0.9 | 1.9 | 1.4 | · | |
| P / Cash Flow | -1.2 | -4.4 | -2.7 | -1.5 | -6.3 | -2.8 | -0.8 | |
| P / FCF | -1.2 | -4.4 | -2.4 | -1.5 | -6.2 | -2.8 | -0.8 | |
| EV / EBITDA | · | · | · | · | · | · | -0.7 | |
| EV / FCF | · | · | · | · | · | · | -0.8 | |
| EV / Revenue | · | · | · | · | · | · | 37.3 | |
| Earnings Yield | -102.2% | -23.8% | -66.7% | -73.1% | -23.7% | -45.6% | · |
आय विवरण 12
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $190.0K | $0 | $0 | $0 | $0 | $0 | $235.0K | $0 | $353.0K | $0 | $0 | $10M | $0 | |
| R&D Expense | $7M | $7M | $11M | $22M | $15M | $12M | $12M | $15M | $14M | $13M | $13M | $10M | $10M | $9M | $15M | $10M | |
| SG&A Expense | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $3M | $3M | $4M | $3M | $3M | $4M | $3M | $3M | $4M | |
| Operating Expenses | $11M | $11M | $15M | $27M | $20M | $16M | $16M | $18M | $17M | $17M | $16M | $13M | $14M | $13M | $18M | $13M | |
| Operating Income | $-11M | $-11M | $-15M | $-27M | $-20M | $-16M | $-16M | $-18M | $-17M | $-17M | $-16M | $-13M | $-14M | $-13M | $-8M | $-13M | |
| Other Non-op | $571.0K | $644.0K | $832.0K | $999.0K | $781.0K | $892.0K | $852.0K | $882.0K | $1M | $1M | $1M | $1M | $1M | $835.0K | $427.0K | $247.0K | |
| Net Income | $-10M | $-11M | $-14M | $-26M | $-20M | $-15M | $-15M | $-17M | $-16M | $-15M | $-15M | $-11M | $-12M | $-12M | $-8M | $-13M | |
| EPS (Basic) | $-0.11 | $-0.11 | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 | $-0.23 | $-0.20 | $-0.22 | $-0.29 | $-0.26 | $-0.46 | |
| EPS (Diluted) | $-0.11 | $-0.11 | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 | $-0.23 | $-0.20 | $-0.22 | $-0.29 | $-0.26 | $-0.46 | |
| Shares (Basic) | 98,069,915 | 98,043,839 | -180,773,543 | 97,153,541 | 90,120,235 | 86,485,126 | -139,905,345 | 75,801,666 | 72,284,351 | 66,080,593 | -101,320,416 | 57,885,393 | 55,143,805 | 41,897,706 | -56,125,244 | 28,663,047 | |
| Shares (Diluted) | 98,069,915 | 98,043,839 | -180,773,543 | 97,153,541 | 90,120,235 | 86,485,126 | -139,905,345 | 75,801,666 | 72,284,351 | 66,080,593 | -101,320,416 | 57,885,393 | 55,143,805 | 41,897,706 | -56,125,244 | 28,663,047 | |
| EBITDA | $-11M | $-11M | · | $-27M | $-20M | $-16M | · | $-18M | $-17M | $-16M | · | $-13M | $-14M | $-13M | · | $-13M |
बैलेंस शीट 20
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $10M | $11M | $6M | $17M | $10M | $11M | $11M | $7M | $7M | $23M | $10M | $12M | $21M | $10M | $18M | |
| Short-term Investments | · | · | · | $79M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $518.0K | $586.0K | $677.0K | $2M | $7M | $6M | $8M | $8M | $10M | $10M | · | $3M | $5M | $3M | · | $6M | |
| Current Assets | $58M | $68M | $80M | $93M | $87M | $83M | $82M | $76M | $90M | $97M | · | $107M | $114M | $119M | · | $85M | |
| PP&E (Net) | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | · | $6M | $6M | $5M | · | $1M | |
| PP&E (Gross) | · | · | $9M | · | · | · | $9M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $5M | · | · | · | $5M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $190.0K | $148.0K | $148.0K | $149.0K | $66.0K | $66.0K | $66.0K | $130.0K | $130.0K | $130.0K | · | $73.0K | $72.0K | $144.0K | · | $169.0K | |
| Total Assets | $70M | $80M | $93M | $107M | $102M | $97M | $97M | $92M | $106M | $113M | · | $125M | $133M | $137M | · | $96M | |
| Accounts Payable | $3M | $3M | $4M | $4M | $4M | $2M | $4M | $4M | $1M | $5M | · | $2M | $516.0K | $4M | · | $3M | |
| Accrued Liabilities | $7M | $7M | $10M | $10M | $10M | $8M | $9M | $9M | $9M | $10M | · | $10M | $11M | $9M | · | $7M | |
| Current Liabilities | $11M | $12M | $15M | $16M | $16M | $11M | $15M | $14M | $12M | $16M | · | $13M | $12M | $14M | · | $11M | |
| Capital Leases | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $11M | $12M | $12M | · | $13M | $13M | $12M | · | $7M | |
| Common Stock | $98.0K | $98.0K | $98.0K | $98.0K | $93.0K | $89.0K | $84.0K | $76.0K | $76.0K | $68.0K | · | $59.0K | $57.0K | $53.0K | · | $29.0K | |
| Paid-in Capital | $676M | $675M | $674M | $672M | $641M | $622M | $602M | $582M | $582M | $568M | · | $552M | $548M | $540M | · | $488M | |
| Retained Earnings | $-627M | $-617M | $-606M | $-592M | $-566M | $-547M | $-532M | $-517M | $-500M | $-484M | · | $-453M | $-442M | $-430M | · | $-410M | |
| AOCI | $-68.0K | $-70.0K | $-8.0K | $-1.0K | $-75.0K | $-66.0K | $-40.0K | $36.0K | $-168.0K | $-158.0K | · | $-294.0K | $-333.0K | $-248.0K | · | $-669.0K | |
| Stockholders' Equity | $49M | $58M | $67M | $80M | $75M | $75M | $70M | $65M | $82M | $84M | · | $98M | $106M | $110M | · | $77M | |
| Liabilities + Equity | $70M | $80M | $93M | $107M | $102M | $97M | $97M | $92M | $106M | $113M | · | $125M | $133M | $137M | · | $96M | |
| Shares Outstanding | 98,087,425 | 98,051,212 | 98,031,104 | 97,986,634 | 92,871,182 | 89,002,825 | 84,038,922 | 75,811,286 | 75,796,198 | 68,354,033 | · | 58,560,061 | 57,046,172 | 53,339,611 | · | 29,009,382 |
नकदी प्रवाह 8
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $168.0K | $162.0K | $166.0K | $165.0K | $166.0K | $167.0K | $175.0K | $178.0K | $177.0K | $178.0K | $175.0K | $176.0K | $161.0K | $80.0K | $39.0K | $49.0K | |
| Other Non-cash | · | $-2M | · | · | · | $-707.0K | · | · | · | $-7M | · | · | · | $11M | · | · | |
| Operating Cash Flow | $-9M | $-13M | $-12M | $-20M | $-14M | $-15M | $-13M | $-13M | $-20M | $-22M | $-11M | $-10M | $-12M | $-590.0K | $-10M | $-12M | |
| CapEx | $73.0K | $138.0K | $31.0K | $37.0K | $9.0K | $0 | $25.0K | $15.0K | $8.0K | $17.0K | $17.0K | $557.0K | $2M | $1M | $1M | $426.0K | |
| Investing Cash Flow | $15M | $11M | $16M | $-20M | $3M | $-4M | $-6M | $18M | $7M | $-1M | $18M | $4M | $-4M | $-38M | $2M | $21M | |
| Financing Cash Flow | $-129.0K | $-142.0K | $-131.0K | $30M | $18M | $19M | $19M | $-105.0K | $13M | $8M | $6M | $3M | $8M | $49M | $918.0K | $3M | |
| Net Change in Cash | $6M | $-1M | $4M | $-11M | $7M | $-1M | $-378.0K | $5M | $-321.0K | $-16M | $13M | $-2M | $-8M | $11M | $-7M | $11M | |
| Free Cash Flow | · | $-13M | · | · | · | $-15M | · | · | · | $-22M | · | · | · | $-2M | · | · |
लाभप्रदता 5
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -14076.3% | · | · | · | · | · | -7079.1% | · | -3573.7% | · | · | · | · | |
| Net Margin | · | · | · | -13549.5% | · | · | · | · | · | -6591.9% | · | -3212.5% | · | · | · | · | |
| EBITDA Margin | · | · | · | -14076.3% | · | · | · | · | · | -7003.4% | · | -3573.7% | · | · | · | · | |
| ROA | -12.0% | -12.2% | · | -26.0% | -18.8% | -14.1% | · | -15.9% | -13.7% | -12.4% | · | -10.3% | -10.8% | -9.9% | · | -12.0% | |
| ROE | -16.7% | -16.2% | · | -35.4% | -25.0% | -18.7% | · | -21.1% | -17.4% | -15.9% | · | -12.9% | -12.8% | -11.5% | · | -13.6% |
तरलता और शोधन क्षमता 2
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 5.8 | · | 5.9 | 5.6 | 7.8 | · | 5.4 | 7.6 | 6.1 | · | 8.3 | 9.3 | 8.7 | · | 7.5 | |
| Quick Ratio | 1.4 | 0.9 | · | 5.4 | 1.1 | 1.0 | · | 0.8 | 0.6 | 0.4 | · | 0.8 | 1.0 | 1.5 | · | 1.6 |
दक्षता 1
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $190.0K | $190.0K | · | $190.0K | $0 | $235.0K | · | $588.0K | $588.0K | $588.0K | · | $353.0K | · | · | · | · | |
| Net Income TTM | $-66M | $-71M | · | $-77M | $-68M | $-64M | · | $-60M | $-55M | $-51M | · | $-49M | $-50M | $-50M | · | $-45M | |
| Market Cap | $59M | $76M | · | $71M | $471M | $269M | · | $133M | $118M | $133M | · | $93M | $123M | $112M | · | $87M | |
| P/E | -0.9 | -1.0 | · | -0.8 | -6.0 | -3.5 | · | -2.0 | -1.8 | -2.1 | · | -1.4 | -1.5 | -1.3 | · | -1.7 | |
| P/S | 308.2 | 402.5 | · | 371.8 | · | 1143.8 | · | 226.9 | 201.1 | 226.7 | · | 262.1 | · | · | · | · | |
| P/B | 1.2 | 1.3 | · | 0.9 | 6.3 | 3.6 | · | 2.0 | 1.4 | 1.6 | · | 0.9 | 1.2 | 1.0 | · | 1.1 | |
| P / Tangible Book | 1.2 | 1.3 | · | 0.9 | 6.3 | 3.6 | · | 2.0 | 1.4 | 1.6 | · | 0.9 | 1.2 | 1.0 | · | 1.1 | |
| P / Cash Flow | · | -6.1 | · | · | · | -17.4 | · | · | · | -6.0 | · | · | · | -189.9 | · | · | |
| P / FCF | · | -6.0 | · | · | · | -17.4 | · | · | · | -6.0 | · | · | · | -61.0 | · | · | |
| Earnings Yield | -117.3% | -97.4% | · | -122.0% | -16.8% | -28.5% | · | -50.6% | -56.4% | -48.2% | · | -74.1% | -65.3% | -77.6% | · | -58.7% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $190.0K | $235.0K | $353.0K | $10M | $0 |
| परिचालन मार्जिन % | -40856.3% | -28899.6% | -15557.8% | -446.8% | — |
| शुद्ध आय | $-74M | $-64M | $-50M | $-45M | $-34M |
| तनुकरणित EPS | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 5.3 | 5.5 | 6.3 | 5.8 | 18.9 |
| त्वरित अनुपात | 0.7 | 0.7 | 1.4 | 0.7 | 0.4 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $-62M | $-69M | $-37M | $-44M | $-33M |
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
📊
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 110 फाइलर्स · $19.3M कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 21 (-14 पिछली तिमाही की तुलना में) | 32 (+24 पिछली तिमाही की तुलना में) | 33 (+9 पिछली तिमाही की तुलना में) | 29 (-7 पिछली तिमाही की तुलना में) | -3.0M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| FEDERATED HERMES, INC. | $5078576 | 8509678 | 26.25% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $2273430 | 3808091 | 11.75% | शेयर |
| AQR CAPITAL MANAGEMENT LLC | $1546546 | 2591397 | 7.99% | शेयर |
| FMR LLC | $1474942 | 2471418 | 7.62% | शेयर |
| Kalehua Capital Management LLC | $1067178 | 1788167 | 5.52% | शेयर |
| UBS Group AG | $794476 | 1330780 | 4.11% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $743104 | 1245147 | 3.84% | शेयर |
| TWO SIGMA ADVISERS, LP | $658861 | 841350 | 3.41% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $574771 | 962604 | 2.97% | शेयर |
| VANGUARD GROUP INC | $508386 | 649280 | 2.63% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $445833 | 747039 | 2.30% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $391531 | 656051 | 2.02% | शेयर |
| JANE STREET GROUP, LLC | $368177 | 616918 | 1.90% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $343947 | 576125 | 1.78% | शेयर |
| STATE STREET CORP | $295387 | 494951 | 1.53% | शेयर |
| H D Vest Advisory Services | $292382 | 57669 | 1.51% | शेयर |
| GOLDMAN SACHS GROUP INC | $226657 | 379788 | 1.17% | शेयर |
| WOLVERINE TRADING, LLC | $163096 | 205100 | 0.84% | कॉल ऑप्शन |
| CITADEL ADVISORS LLC | $148603 | 249000 | 0.77% | कॉल ऑप्शन |
| XTX Topco Ltd | $135281 | 226678 | 0.70% | शेयर |
| NORTHERN TRUST CORP | $131380 | 220141 | 0.68% | शेयर |
| WOLVERINE TRADING, LLC | $110453 | 138900 | 0.57% | पुट ऑप्शन |
| BANK OF AMERICA CORP /DE/ | $108971 | 182838 | 0.56% | शेयर |
| JANE STREET GROUP, LLC | $106588 | 178600 | 0.55% | कॉल ऑप्शन |
| RENAISSANCE TECHNOLOGIES LLC | $98604 | 165222 | 0.51% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92880 | 154800 | 0.48% | कॉल ऑप्शन |
| JPMORGAN CHASE & CO | $83679 | 147739 | 0.43% | शेयर |
| GROUP ONE TRADING LLC | $82882 | 138878 | 0.43% | शेयर |
| Qube Research & Technologies Ltd | $75791 | 126996 | 0.39% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $69900 | 116500 | 0.36% | पुट ऑप्शन |
| WOLVERINE TRADING, LLC | $42961 | 54026 | 0.22% | शेयर |
| HSBC HOLDINGS PLC | $38361 | 66185 | 0.20% | शेयर |
| BlackRock, Inc. | $35972 | 60274 | 0.19% | शेयर |
| Mariner, LLC | $34998 | 58658 | 0.18% | शेयर |
| CITADEL ADVISORS LLC | $34137 | 57200 | 0.18% | पुट ऑप्शन |
| HOHIMER WEALTH MANAGEMENT, LLC | $32824 | 55000 | 0.17% | शेयर |
| MERCER GLOBAL ADVISORS INC /ADV | $31947 | 53531 | 0.17% | शेयर |
| KINGSWOOD WEALTH ADVISORS, LLC | $31034 | 52000 | 0.16% | शेयर |
| Schonfeld Strategic Advisors LLC | $30364 | 50880 | 0.16% | शेयर |
| ADAR1 Capital Management, LLC | $30249 | 50685 | 0.16% | शेयर |
| Alpha Wealth Funds, LLC | $29890 | 50000 | 0.15% | शेयर |
| CWM, LLC | $28088 | 36010 | 0.15% | शेयर |
| Creative Planning | $24823 | 41593 | 0.13% | शेयर |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $23925 | 43948 | 0.12% | शेयर |
| Point72 Asset Management, L.P. | $22248 | 37278 | 0.11% | शेयर |
| Hobbs Group Advisors, LLC | $21480 | 35992 | 0.11% | शेयर |
| LPL Financial LLC | $21216 | 35549 | 0.11% | शेयर |
| CITADEL ADVISORS LLC | $20884 | 34994 | 0.11% | शेयर |
| CAPTRUST FINANCIAL ADVISORS | $20259 | 33946 | 0.10% | शेयर |
| Vanguard Global Advisers, LLC | $19948 | 33414 | 0.10% | शेयर |
| RHUMBLINE ADVISERS | $18155 | 30412 | 0.09% | शेयर |
| Rockefeller Capital Management L.P. | $16781 | 28118 | 0.09% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $16657 | 27911 | 0.09% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $14953 | 25055 | 0.08% | शेयर |
| BARCLAYS PLC | $14382 | 24099 | 0.07% | शेयर |
| Balyasny Asset Management L.P. | $13735 | 23015 | 0.07% | शेयर |
| Y-Intercept (Hong Kong) Ltd | $13352 | 22373 | 0.07% | शेयर |
| Abel Hall, LLC | $13199 | 22117 | 0.07% | शेयर |
| Steward Partners Investment Advisory, LLC | $11697 | 19600 | 0.06% | शेयर |
| Tower Research Capital LLC (TRC) | $10893 | 18252 | 0.06% | शेयर |
| MAI Capital Management | $10054 | 16846 | 0.05% | शेयर |
| TRUST CO OF TOLEDO NA /OH/ | $9931 | 16640 | 0.05% | शेयर |
| Arax Advisory Partners | $9882 | 16557 | 0.05% | शेयर |
| JANE STREET GROUP, LLC | $8952 | 15000 | 0.05% | पुट ऑप्शन |
| Vanguard Personalized Indexing Management, LLC | $8892 | 14899 | 0.05% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $7861 | 13172 | 0.04% | शेयर |
| Cerity Partners LLC | $7624 | 12775 | 0.04% | शेयर |
| DIADEMA PARTNERS LP | $7460 | 12500 | 0.04% | पुट ऑप्शन |
| TORONTO DOMINION BANK | $7281 | 12200 | 0.04% | कॉल ऑप्शन |
| BRIGHTON JONES LLC | $6839 | 11458 | 0.04% | शेयर |
| Gladstone Institutional Advisory LLC | $6744 | 11300 | 0.03% | शेयर |
| My Portfolio Guide, LLC | $5460 | 7000 | 0.03% | शेयर |
| MARSHALL WACE, LLP | $5339 | 8899 | 0.03% | शेयर |
| Persistent Asset Partners Ltd | $5213 | 27 | 0.03% | पुट ऑप्शन |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4048 | 5190 | 0.02% | शेयर |
| Integrated Wealth Concepts LLC | $3577 | 5995 | 0.02% | शेयर |
| WELLS FARGO & COMPANY/MN | $2984 | 5000 | 0.02% | शेयर |
| MORGAN STANLEY | $2461 | 4123 | 0.01% | शेयर |
| Allworth Financial LP | $2158 | 3615 | 0.01% | शेयर |
| GSA CAPITAL PARTNERS LLP | $2062 | 3454863 | 0.01% | शेयर |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $1569 | 2011 | 0.01% | शेयर |
| Ares Financial Consulting, LLC | $1194 | 2000 | 0.01% | शेयर |
| NFSG Corp | $1181 | 1979 | 0.01% | शेयर |
| Vision Retirement, LLC | $895 | 1500 | 0.00% | शेयर |
| MCF Advisors LLC | $836 | 1400 | 0.00% | शेयर |
| JONES FINANCIAL COMPANIES LLLP | $791 | 1500 | 0.00% | शेयर |
| PNC Financial Services Group, Inc. | $762 | 1276 | 0.00% | शेयर |
| CITIGROUP INC | $537 | 900 | 0.00% | शेयर |
| ROTHSCHILD INVESTMENT LLC | $528 | 885 | 0.00% | शेयर |
| Clearstead Advisors, LLC | $515 | 861 | 0.00% | शेयर |
| Essential Partners LLC | $486 | 815 | 0.00% | शेयर |
| GAMMA Investing LLC | $393 | 659 | 0.00% | शेयर |
| True Wealth Design, LLC | $277 | 464 | 0.00% | शेयर |
| Farther Finance Advisors, LLC | $222 | 372 | 0.00% | शेयर |
| SJS Investment Consulting Inc. | $125 | 208 | 0.00% | शेयर |
| Larson Financial Group LLC | $90 | 150 | 0.00% | शेयर |
| EverSource Wealth Advisors, LLC | $88 | 148 | 0.00% | शेयर |
| IFP Advisors, Inc | $85 | 143 | 0.00% | शेयर |
| HRT FINANCIAL LP | $75 | 126681 | 0.00% | शेयर |
| CALDWELL SUTTER CAPITAL, INC. | $31 | 52 | 0.00% | शेयर |
कंपनी के अंदरूनी सूत्र 33 इनसाइडर्स · 17 अधिकारी · 11 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Sanjay Shukla | President and CEO | 3 फ़रवरी 2026 M | 153553 | 0 | 1 | $-3670 |
| Jill Marie Broadfoot | Chief Financial Officer | 3 फ़रवरी 2026 M | 37296 | 0 | 1 | $-1527 |
| Stan Blackburn | Acting Chief Financial Officer | 27 जनवरी 2016 A | — | 0 | 0 | $0 |
| Frederic Chereau | President & COO | 6 मई 2015 A | — | 0 | 0 | $0 |
| Nancy Krueger | General Counsel | 3 फ़रवरी 2026 M | 33124 | 0 | 1 | $-1096 |
| Ashraf Amanullah | Senior Vice President, Biologics Development and Manufacturing | 31 मई 2018 M | 26264 | 0 | 0 | $0 |
| John T Blake | Senior Vice President, Finance | 7 फ़रवरी 2018 M | 1932 | 0 | 0 | $0 |
| David John King | Chief Scientific Officer | 6 फ़रवरी 2018 A | — | 0 | 0 | $0 |
| Sanuj K. Ravindran | Chief Business Officer | 7 फ़रवरी 2017 A | — | 0 | 0 | $0 |
| Andrew Cubitt | VP, Product Protection | 13 सितमबर 2016 A | — | 0 | 0 | $0 |
| Kelly Blackburn | VP, Clinical Affairs | 28 मार्च 2016 A | — | 0 | 0 | $0 |
| Melissa A. Ashlock | SVP, Translational Medicine and Therapeutics | 27 जनवरी 2016 A | — | 0 | 0 | $0 |
| John C. Mckew | VP, Research | 27 जनवरी 2016 A | — | 0 | 0 | $0 |
| Holly D. Chrzanowski | VP, Enterprise Talent & Organization | 27 जनवरी 2016 A | — | 0 | 0 | $0 |
| Marcy Graham | VP, Investor Relations and Corporate Communications | 4 जनवरी 2016 A | — | 0 | 0 | $0 |
| Fred Ramsdell | VP, Immunology | 1 अक्टूबर 2015 A | — | 0 | 0 | $0 |
| David M. Weiner | Chief Medical Officer | 6 मई 2015 A | — | 0 | 0 | $0 |
| Svetlana Lucas | निदेशक | 1 मई 2025 A | 6000 | 0 | 0 | $0 |
| Jane A Gross | निदेशक | 1 मई 2025 A | 9750 | 0 | 0 | $0 |
| Eric Benevich | निदेशक | 1 मई 2025 A | — | 0 | 0 | $0 |
| Sara Zaknoen | निदेशक | 1 मई 2025 A | 6000 | 0 | 0 | $0 |
| John K Clarke | निदेशक | 22 मई 2024 A | 19797 | 0 | 0 | $0 |
| Jeffrey S. Hatfield | निदेशक | 6 मई 2020 A | — | 0 | 0 | $0 |
| John Mendlein | निदेशक | 8 मई 2019 A | 615382 | 0 | 0 | $0 |
| BLAIR JAMES C | निदेशक | 8 मई 2019 A | — | 0 | 0 | $0 |
| Amir Nashat | निदेशक | 15 मई 2018 A | 17638 | 0 | 0 | $0 |
| Kathryn E Falberg | निदेशक | 24 मई 2016 A | — | 0 | 0 | $0 |
| EcoR1 Capital Fund Qualified, L.P. | 10% मालिक | 16 मई 2018 S | 0 | 0 | 0 | $0 |
| Timothy Coughlin | — | 11 मई 2026 A | 56000 | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 11 मई 2026 A | 1413023 | 2 | 0 | $912720 |
| Mark Alan Goldberg | — | 9 मई 2017 A | — | 0 | 0 | $0 |
| Srinivas Akkaraju | — | 9 मई 2017 A | 1866126 | 0 | 0 | $0 |
| Grove Matsuoka | — | 7 फ़रवरी 2017 A | 12412 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 3 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| PAUL SCHIMMEL, PAUL SCHIMMEL PROTOTYPE PSP, PAUL SCHIMMEL, TRUSTEE, FBO PAUL SCHIMMEL ×3 फाइलिंग | 14 फ़रवरी 2020 | — | प्रारंभिक फाइलिंग | — | SEC |
| Polaris Venture Partners V, L.P. (“PVP V”), Polaris Venture Partners Entrepreneurs’ Fund V, L.P. (“PVPE V”), Polaris Venture Partners Founders’ Fund V, L.P. (“PVPFF V”), Polaris Venture Partners Special Founders’ Fund V, L.P. (“PVPSFF V”), Polaris Venture Management Co. V, L.L.C. (“PVM V”), Jonathan A. Flint, Terrance G. McGuire, Amir Nashat ×2 फाइलिंग | 17 जुलाई 2019 | — | प्रारंभिक फाइलिंग | — | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×3 फाइलिंग | 12 फ़रवरी 2019 | — | प्रारंभिक फाइलिंग | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 8 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| ITWO · ProShares Trust | 0.00% | 4514 NS | 31 मई 2026 | N-PORT |
| UWM · ProShares Trust | 0.00% | 3530 NS | 31 मई 2026 | N-PORT |
| URTY · ProShares Trust | 0.00% | 3569 NS | 31 मई 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 4536 NS | 31 मई 2026 | N-PORT |
| HDG · ProShares Trust | 0.00% | 90 NS | 31 मई 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 1054556 SH | 8 अगस्त 2026 | दैनिक |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2650788 SH | 8 अगस्त 2026 | दैनिक |
| DFAC · Dimensional ETF Trust | 0.00% | 3126 NS | 30 अप्रैल 2026 | N-PORT |